Artificial intelligence system can help prevent anemia in patients undergoing hemodialysis

IMAGE: AISACS received a total of five inputs and churned out dosage direction probabilities for erythropoiesis-stimulating agents and iron supplements. It was noted that AISACS sometimes produces "clinically appropriate " directions that... view more Anemia, a condition characterized by the lack of healthy red blood cells in the body, is common in patients with chronic kidney disease who need to undergo routine hemodialysis (a process that helps to "clean" the blood when the kidneys don't function well). Thus, red blood cell-stimulating agents (called "erythropoiesis-stimulating agents" or ESAs) and iron supplements (ISs) are administered as part of this process. But, complications can arise if the patients have an altered iron metabolism or poor response to medications. Moreover, the medications tend to be expensive and impose a heavy financial burden on public health.